A Grading System of Microvascular Invasion for Patients with Hepatocellular Carcinoma Undergoing Liver Resection with Curative Intent: A Multicenter Study

References

• Torbenson M, Ng I, Park Y, Roncalli M, Sakamato M. Hepatocellular carcinoma. In: WHO Classification of Tumours, Digestive System Tumours. Lyon: IARC Press; 2019:229–239.
   Google Scholar
• Vos T, Lim SS, Abbafati C, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204–1222. doi:10.1016/s0140-6736(20)30925-9
   PubMed Web of Science ®Google Scholar
• Toh MR, Wong EYT, Wong SH, et al. Global epidemiology and genetics of hepatocellular carcinoma. Gastroenterology. 2023;164(5):766–782. doi:10.1053/j.gastro.2023.01.033
   PubMed Web of Science ®Google Scholar
• Portolani N, Coniglio A, Ghidoni S, et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg. 2006;243(2):229–235. doi:10.1097/01.sla.0000197706.21803.a1
   PubMed Web of Science ®Google Scholar
• Wang H, Wu MC, Cong WM. Microvascular invasion predicts a poor prognosis of solitary hepatocellular carcinoma up to 2 cm based on propensity score matching analysis. Hepatol Res. 2019;49(3):344–354. doi:10.1111/hepr.13241
   PubMed Web of Science ®Google Scholar
• Wang H, Feng LH, Qian YW, Cao ZY, Wu MC, Cong WM. Does microvascular invasion in Barcelona clinic liver cancer stage A multinodular hepatocellular carcinoma indicate early-stage behavior? Ann Transl Med. 2019;7(18):428. doi:10.21037/atm.2019.08.114
   PubMed Web of Science ®Google Scholar
• Wang H, Qian YW, Wu MC, Cong WM. Liver resection is justified in patients with BCLC intermediate stage hepatocellular carcinoma without microvascular invasion. J Gastrointest Surg. 2020;24(12):2737–2747. doi:10.1007/s11605-019-04251-8
   PubMed Web of Science ®Google Scholar
• Erstad DJ, Tanabe KK. Prognostic and therapeutic implications of microvascular invasion in hepatocellular carcinoma. Ann Surg Oncol. 2019;26(5):1474–1493. doi:10.1245/s10434-019-07227-9
   PubMed Web of Science ®Google Scholar
• Wang Z, Ren Z, Chen Y, et al. Adjuvant transarterial chemoembolization for HBV-related hepatocellular carcinoma after resection: a randomized controlled study. Clin Cancer Res. 2018;24(9):2074–2081. doi:10.1158/1078-0432.Ccr-17-2899
   PubMed Web of Science ®Google Scholar
• Li SH, Mei J, Cheng Y, et al. Postoperative adjuvant hepatic arterial infusion chemotherapy with FOLFOX in hepatocellular carcinoma with microvascular invasion: a multicenter, phase III, randomized study. J Clin Oncol. 2023;41(10):1898–1908. doi:10.1200/jco.22.01142
   PubMed Web of Science ®Google Scholar
• Shi C, Li Y, Geng L, et al. Adjuvant stereotactic body radiotherapy after marginal resection for hepatocellular carcinoma with microvascular invasion: a randomised controlled trial. Eur J Cancer. 2022;166:176–184. doi:10.1016/j.ejca.2022.02.012
   PubMed Web of Science ®Google Scholar
• Hack SP, Spahn J, Chen M, et al. IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. Future Oncol. 2020;16(15):975–989. doi:10.2217/fon-2020-0162
   PubMed Web of Science ®Google Scholar
• Sahin IH, Khalil L, Millett R, Kaseb A. Neoadjuvant and adjuvant treatment approaches for hepatocellular carcinoma: future outlook. Chin Clin Oncol. 2021;10(1):7. doi:10.21037/cco-20-248
   PubMed Web of Science ®Google Scholar
• Xu XF, Diao YK, Zeng YY, et al. Association of severity in the grading of microvascular invasion with long-term oncological prognosis after liver resection for early-stage hepatocellular carcinoma: a multicenter retrospective cohort study from a hepatitis B virus-endemic area. Int J Surg. 2023;109(4):841–849. doi:10.1097/js9.0000000000000325
   PubMed Web of Science ®Google Scholar
• Chen ZH, Zhang XP, Wang H, et al. Effect of microvascular invasion on the postoperative long-term prognosis of solitary small HCC: a systematic review and meta-analysis. HPB. 2019;21(8):935–944. doi:10.1016/j.hpb.2019.02.003
   PubMed Web of Science ®Google Scholar
• Cong WM, Bu H, Chen J, et al. Practice guidelines for the pathological diagnosis of primary liver cancer: 2015 update. World J Gastroenterol. 2016;22(42):9279–9287. doi:10.3748/wjg.v22.i42.9279
   PubMed Web of Science ®Google Scholar
• Sheng X, Ji Y, Ren GP, et al. A standardized pathological proposal for evaluating microvascular invasion of hepatocellular carcinoma: a multicenter study by LCPGC. Hepatol Int. 2020;14(6):1034–1047. doi:10.1007/s12072-020-10111-4
   PubMed Web of Science ®Google Scholar
• Cheng S, Chen M, Cai J. Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus: 2016 edition. Oncotarget. 2017;8(5):8867–8876. doi:10.18632/oncotarget.12817
   PubMedGoogle Scholar
• Chua TC, Morris DL. Exploring the role of resection of extrahepatic metastases from hepatocellular carcinoma. Surg Oncol. 2012;21(2):95–101. doi:10.1016/j.suronc.2011.01.005
   PubMed Web of Science ®Google Scholar
• Zhong X, Peng J, Xie Y, et al. A nomogram based on multi-modal ultrasound for prediction of microvascular invasion and recurrence of hepatocellular carcinoma. Eur J Radiol. 2022;151:110281. doi:10.1016/j.ejrad.2022.110281
   PubMed Web of Science ®Google Scholar
• Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer. 1954;7(3):462–503. doi:10.1002/1097-0142(195405)7:3<462::aid-cncr2820070308>3.0.co;2-e
   PubMed Web of Science ®Google Scholar
• Pang YY, Belghiti J, Clavien P-A. The Brisbane 2000 terminology of liver anatomy and resections. HPB. 2000;2:333–339. doi:10.1080/136518202760378489
   Google Scholar
• Wakabayashi G, Cherqui D, Geller DA, et al. The Tokyo 2020 terminology of liver anatomy and resections: updates of the Brisbane 2000 system. J Hepatobiliary Pancreat Sci. 2022;29(1):6–15. doi:10.1002/jhbp.1091
   PubMed Web of Science ®Google Scholar
• Chun YS, Pawlik TM, Vauthey JN. Edition of the AJCC cancer staging manual: pancreas and hepatobiliary cancers. Ann Surg Oncol. 2018;25(4):845–847. doi:10.1245/s10434-017-6025-x
   PubMed Web of Science ®Google Scholar
• Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681–693. doi:10.1016/j.jhep.2021.11.018
   PubMed Web of Science ®Google Scholar
• Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;38(2):200–207. doi:10.1016/s0168-8278(02)00360-4
   PubMed Web of Science ®Google Scholar
• Nitta H, Allard MA, Sebagh M, et al. Prognostic value and prediction of extratumoral microvascular invasion for hepatocellular carcinoma. Ann Surg Oncol. 2019;26(8):2568–2576. doi:10.1245/s10434-019-07365-0
   PubMed Web of Science ®Google Scholar
• Heinze G, Wallisch C, Dunkler D. Variable selection - A review and recommendations for the practicing statistician. Biom J. 2018;60(3):431–449. doi:10.1002/bimj.201700067
   PubMed Web of Science ®Google Scholar
• Zhang X, Li J, Shen F, Lau WY. Significance of presence of microvascular invasion in specimens obtained after surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol. 2018;33(2):347–354. doi:10.1111/jgh.13843
   PubMed Web of Science ®Google Scholar
• Isik B, Gonultas F, Sahin T, Yilmaz S. Microvascular venous invasion in hepatocellular carcinoma: why do recurrences occur? J Gastrointest Cancer. 2020;51(4):1133–1136. doi:10.1007/s12029-020-00487-9
   PubMed Web of Science ®Google Scholar
• Kim SH, Moon DB, Park YH, et al. Favorable prognostic factors for survival outcomes of hepatocellular carcinoma with portal vein tumor thrombosis after hepatectomy. Ann Surg Oncol. 2023;30(7):4279–4289. doi:10.1245/s10434-023-13316-7
   PubMedGoogle Scholar
• Pan Y, Yang L, Cao Y, et al. Factors influencing the prognosis patients with Barcelona clinic liver cancer stage C hepatocellular carcinoma undergoing salvage surgery after conversion therapy. Transl Cancer Res. 2023;12(7):1852–1862. doi:10.21037/tcr-23-70
   PubMed Web of Science ®Google Scholar
• Li J, Yang F, Li J, Huang ZY, Cheng Q, Zhang EL. Postoperative adjuvant therapy for hepatocellular carcinoma with microvascular invasion. World J Gastrointest Surg. 2023;15(1):19–31. doi:10.4240/wjgs.v15.i1.19
   PubMedGoogle Scholar
• Feng X, Feng GY, Tao J, et al. Comparison of different adjuvant therapy regimen efficacies in patients with high risk of recurrence after radical resection of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2023;149(12):10505–10518. doi:10.1007/s00432-023-04874-0
   PubMed Web of Science ®Google Scholar
• Qin S, Chen M, Cheng AL, et al. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, Phase 3 trial. Lancet. 2023;402(10415):1835–1847. doi:10.1016/s0140-6736(23)01796-8
   PubMed Web of Science ®Google Scholar
• Zhang XP, Xu S, Lin ZY, et al. Significance of anatomical resection and resection margin status in patients with HBV-related hepatocellular carcinoma and microvascular invasion: a multicenter propensity score-matched study. Int J Surg. 2023;109(4):679–688. doi:10.1097/js9.0000000000000204
   PubMed Web of Science ®Google Scholar
• Liu J, Zhuang G, Bai S, et al. The comparison of surgical margins and type of hepatic resection for hepatocellular carcinoma with microvascular invasion. Oncologist. 2023. doi:10.1093/oncolo/oyad124
   Web of Science ®Google Scholar
• Kong J, Liang X, Zhang J, Zeng J, Liu J, Zeng J. Antiviral therapy improves survival in hepatocellular carcinoma with microvascular invasion: a propensity score analysis. Dig Dis Sci. 2022;67(8):4250–4257. doi:10.1007/s10620-021-07248-z
   PubMed Web of Science ®Google Scholar
• Feng LH, Zhu YY, Zhou JM, et al. Adjuvant TACE may not improve recurrence-free or overall survival in HCC patients with low risk of recurrence after hepatectomy. Front Oncol. 2023;13:1104492. doi:10.3389/fonc.2023.1104492
   PubMed Web of Science ®Google Scholar
• Liu S, Li H, Guo L, et al. Tumor size affects efficacy of adjuvant transarterial chemoembolization in patients with hepatocellular carcinoma and microvascular invasion. Oncologist. 2019;24(4):513–520. doi:10.1634/theoncologist.2018-0305
   PubMed Web of Science ®Google Scholar
• Roayaie S, Blume IN, Thung SN, et al. A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology. 2009;137(3):850–855. doi:10.1053/j.gastro.2009.06.003
   PubMed Web of Science ®Google Scholar
• Fujita N, Aishima S, Iguchi T, et al. Histologic classification of microscopic portal venous invasion to predict prognosis in hepatocellular carcinoma. Hum Pathol. 2011;42(10):1531–1538. doi:10.1016/j.humpath.2010.12.016
   PubMed Web of Science ®Google Scholar
• Iguchi T, Shirabe K, Aishima S, et al. New pathologic stratification of microvascular invasion in hepatocellular carcinoma: predicting prognosis after living-donor liver transplantation. Transplantation. 2015;99(6):1236–1242. doi:10.1097/tp.0000000000000489
   PubMed Web of Science ®Google Scholar
• Sumie S, Nakashima O, Okuda K, et al. The significance of classifying microvascular invasion in patients with hepatocellular carcinoma. Ann Surg Oncol. 2014;21(3):1002–1009. doi:10.1245/s10434-013-3376-9
   PubMed Web of Science ®Google Scholar
• Zhao H, Chen C, Fu X, et al. Prognostic value of a novel risk classification of microvascular invasion in patients with hepatocellular carcinoma after resection. Oncotarget. 2017;8(3):5474–5486. doi:10.18632/oncotarget.12547
   PubMedGoogle Scholar
• Feng LH, Dong H, Lau WY, et al. Novel microvascular invasion-based prognostic nomograms to predict survival outcomes in patients after R0 resection for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2017;143(2):293–303. doi:10.1007/s00432-016-2286-1
   PubMed Web of Science ®Google Scholar
• Liao B, Liu L, Wei L, et al. Innovative synoptic reporting with seven-point sampling protocol to improve detection rate of microvascular invasion in hepatocellular carcinoma. Front Oncol. 2021;11:726239. doi:10.3389/fonc.2021.726239
   PubMed Web of Science ®Google Scholar
• Zhang EL, Cheng Q, Huang ZY, Dong W. Revisiting surgical strategies for hepatocellular carcinoma with microvascular invasion. Front Oncol. 2021;11:691354. doi:10.3389/fonc.2021.691354
   PubMed Web of Science ®Google Scholar
• Gao Q, Zhu H, Dong L, et al. Integrated proteogenomic characterization of HBV-related hepatocellular carcinoma. Cell. 2019;179(2):561–577.e522. doi:10.1016/j.cell.2019.08.052
   PubMed Web of Science ®Google Scholar
• Amaddeo G, Cao Q, Ladeiro Y, et al. Integration of tumour and viral genomic characterizations in HBV-related hepatocellular carcinomas. Gut. 2015;64(5):820–829. doi:10.1136/gutjnl-2013-306228
   PubMed Web of Science ®Google Scholar
• Shi Y, Song Q, Yu S, Hu D, Zhuang X. Microvascular invasion in hepatocellular carcinoma overexpression promotes cell proliferation and inhibits cell apoptosis of hepatocellular carcinoma via inhibiting miR-199a expression. Onco Targets Ther. 2015;8:2303–2310. doi:10.2147/ott.S86807
   PubMed Web of Science ®Google Scholar
• Liu M, Wang L, Zhu H, et al. A preoperative measurement of serum microRNA-125b may predict the presence of microvascular invasion in hepatocellular carcinomas patients. Transl Oncol. 2016;9(3):167–172. doi:10.1016/j.tranon.2016.03.002
   PubMed Web of Science ®Google Scholar
• Xu L, Zhang M, Zheng X, Yi P, Lan C, Xu M. The circular RNA ciRS-7 (Cdr1as) acts as a risk factor of hepatic microvascular invasion in hepatocellular carcinoma. J Cancer Res Clin Oncol. 2017;143(1):17–27. doi:10.1007/s00432-016-2256-7
   PubMed Web of Science ®Google Scholar
• Yuan SX, Yang F, Yang Y, et al. Long noncoding RNA associated with microvascular invasion in hepatocellular carcinoma promotes angiogenesis and serves as a predictor for hepatocellular carcinoma patients’ poor recurrence-free survival after hepatectomy. Hepatology. 2012;56(6):2231–2241. doi:10.1002/hep.25895
   PubMed Web of Science ®Google Scholar
• Lu J, Li B, Xiong X, Cheng N. RNA sequencing reveals the long noncoding RNA and mRNA profiles and identifies long non-coding RNA TSPAN12 as a potential microvascular invasion-related biomarker in hepatocellular carcinoma. Biomed Pharmacother. 2020;126:110111. doi:10.1016/j.biopha.2020.110111
   PubMed Web of Science ®Google Scholar
• Cai Y, Fu Y, Liu C, et al. Stathmin 1 is a biomarker for diagnosis of microvascular invasion to predict prognosis of early hepatocellular carcinoma. Cell Death Dis. 2022;13(2):176. doi:10.1038/s41419-022-04625-y
   PubMed Web of Science ®Google Scholar
• Qi LN, Ma L, Wu FX, et al. S100P as a novel biomarker of microvascular invasion and portal vein tumor thrombus in hepatocellular carcinoma. Hepatol Int. 2021;15(1):114–126. doi:10.1007/s12072-020-10130-1
   PubMed Web of Science ®Google Scholar
• Zhao X, Wang Y, Xia H, et al. Roles and molecular mechanisms of biomarkers in hepatocellular carcinoma with microvascular invasion: a review. J Clin Transl Hepatol. 2023;11(5):1170–1183. doi:10.14218/jcth.2022.00013s
   PubMed Web of Science ®Google Scholar
• Ke L, Rui Z, Fukai W, et al. Single-cell dissection of the multicellular ecosystem and molecular features underlying microvascular invasion in hepatocellular carcinoma. Hepatology. 2023. doi:10.1097/hep.0000000000000673
   Web of Science ®Google Scholar
• Summers RM. Radiomics to predict microvascular invasion in hepatocellular carcinoma: a promising biomarker for tumor recurrence. Radiology. 2023;307(4):e230657. doi:10.1148/radiol.230657
   PubMed Web of Science ®Google Scholar
• Fan Z, Jin M, Zhang L, et al. From clinical variables to multiomics analysis: a margin morphology-based gross classification system for hepatocellular carcinoma stratification. Gut. 2023;72(11):2149–2163. doi:10.1136/gutjnl-2023-330461
   PubMed Web of Science ®Google Scholar
• Pelizzaro F, Trevisani F, Simeon V, et al. Predictors of non-transplantable recurrence in hepatocellular carcinoma patients treated with frontline liver resection. Liver Int. 2023;43(12):2762–2775. doi:10.1111/liv.15719
   PubMed Web of Science ®Google Scholar